Literature DB >> 11189690

Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

J L Weissfeld1, R M Fagerstrom, B O'Brien.   

Abstract

Investigators for the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial describe quality control procedures for the digital rectal examination, ovarian palpation examination, transvaginal ultrasound, chest X-ray, and flexible sigmoidoscopy. These cancer screening tests are subjective and difficult to standardize. PLCO quality control procedures aim to measure and, where possible, reduce variation, across examiner and screening center, with respect to cancer screening test performance. Initial protocols stressed examiner qualifications, experience, and training; equipment specifications; examination procedures; and definitions for positive tests. The PLCO quality assurance subcommittee developed a final quality assurance plan, which included central approval and registration of PLCO examiners, direct observation of screening test performance during periodic site visits by the National Cancer Institute and coordinating center auditors, periodic analysis of screening test data, and procedures for independently duplicating or reviewing selected examinations. For each modality, the periodic data analyses examine the test-positive and the test-inadequate proportions and aim to identify divergent centers or examiners. Procedures for duplicating examinations specify feasible sample sizes for precise estimates of agreement between examiners, at each center, for each screening test modality, and over a 1-year period. These quality control procedures will help characterize the consistency and reliability of the PLCO cancer screening tests.

Entities:  

Mesh:

Year:  2000        PMID: 11189690     DOI: 10.1016/s0197-2456(00)00094-5

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  4 in total

1.  Cumulative incidence of false-positive results in repeated, multimodal cancer screening.

Authors:  Jennifer Miller Croswell; Barnett S Kramer; Aimee R Kreimer; Phil C Prorok; Jian-Lun Xu; Stuart G Baker; Richard Fagerstrom; Thomas L Riley; Jonathan D Clapp; Christine D Berg; John K Gohagan; Gerald L Andriole; David Chia; Timothy R Church; E David Crawford; Mona N Fouad; Edward P Gelmann; Lois Lamerato; Douglas J Reding; Robert E Schoen
Journal:  Ann Fam Med       Date:  2009 May-Jun       Impact factor: 5.166

Review 2.  Korean clinical practice guideline for benign prostatic hyperplasia.

Authors:  Jeong Kyun Yeo; Hun Choi; Jae Hyun Bae; Jae Heon Kim; Seong Ok Yang; Chul Young Oh; Young Sam Cho; Kyoung Woo Kim; Hyung Ji Kim
Journal:  Investig Clin Urol       Date:  2016-01-11

3.  Novel ultrasound-based volume estimation of prostatic benign enlargement to improve decision-making on surgical approach.

Authors:  Snir Dekalo; Ziv Savin; Eran Schreter; Ron Marom; Yuval Bar-Yosef; Roy Mano; Ofer Yossepowitch; Mario Sofer
Journal:  Ther Adv Urol       Date:  2021-02-11

4.  Glycemic Index, Glycemic Load, and Risk of Ovarian Cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cohort.

Authors:  Jennifer M Mongiovi; Jo L Freudenheim; Kirsten B Moysich; Susan E McCann
Journal:  J Nutr       Date:  2021-06-01       Impact factor: 4.798

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.